BACKGROUND: Emphysema has considerable variability in its regional distribution. Craniocaudal emphysema distribution is an important predictor of the response to lung volume reduction. However, there is little consensus regarding how to define upper lobepredominant and lower lobe-predominant emphysema subtypes. Consequently, the clinical and genetic associations with these subtypes are poorly characterized.
Emphysema exhibits considerable heterogeneity in its extent and spatial distribution. 1 Although total lung emphysema is a strong predictor of many COPD-related outcomes, the craniocaudal distribution of emphysema is an independent predictor of mortality and the response to lung volume reduction. [2] [3] [4] [5] [6] Emphysema distribution is partially genetically determined, with an estimated heritability of 20%, and genome-wide association studies (GWAS) of this trait as a continuous measure have identified multiple genome-wide significant associations. 7, 8 Thus, emphysema distribution is a COPD phenotype with both clinical and biological relevance.
Most previous studies have evaluated emphysema distribution as a continuous trait, but for treatment decisions and clinical trials, it is often useful to define groups of subjects based on specific disease characteristics. However, although there is compelling evidence that emphysema distribution is an important facet of COPD clinical heterogeneity, approaches to define groups of subjects according to upper-lobe or lower-lobe emphysema predominance independent of other disease markers are needed to enable better characterization of these subtypes. In addition, defining emphysema distribution subgroups through the use of thresholds for an emphysema ratio often results in an imbalance in the amount of total emphysema between groups.
In the present study, we sought to identify subgroups of smokers characterized by upper-lobe or lower-lobe emphysema predominance and comparable amounts of total emphysema. We hypothesized that these emphysema distribution subtypes would have different clinical characteristics and genetic associations. To test this hypothesis, we used a data-driven clustering approach to identify upper lobe-predominant and lower lobe-predominant emphysema subgroups with comparable amounts of total emphysema, and we characterized these subgroups using extensive phenotypic and genotypic data from the COPDGene study at baseline and at 5-year follow-up.
Methods

Study Population
The COPDGene study is an ongoing large multicenter longitudinal study designed to investigate the genetic and epidemiologic characteristics of COPD. The protocols for subject recruitment and data collection for the COPDGene study have been previously described. 9 During phase I, the COPDGene study enrolled 10,192 non-Hispanic white and African American subjects across the full spectrum of disease severity as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric grading system. Eight individuals had Pi ZZ or ZNull a 1 -antitrypsin deficiency and were excluded in this present study. During phase II, 5,000 subjects had completed their 5-year follow-up visit at the time of this analysis (COPDGene phase II data set, September 24, 2016) . Nineteen of these 5,000 subjects underwent lung volume reduction surgery or lung transplantation between the two visits and were excluded from this analysis. Written informed consent was obtained from all participants. The study and consent forms were approved by the Brigham and Women's Hospital Institutional Review Board (No. 2007P000554/BWH).
CT Measurements
Using 3D SLICER analysis (www.chestimagingplatform.org) at visit 1 and Thirona software (www.thirona.eu) at visit 2, emphysema was quantified as the percentage of lung voxels with attenuation lower than -950 HU at maximal inspiration (% LAA-950). 10 The lungs were automatically segmented into anatomically defined lung lobes, as previously described, 11 and % LAA-950 was quantified in each lobe. The lingula was included in the left upper lobe measurements. The ratio of % LAA-950 in both upper lobes to that in both lower lobes was used to evaluate the lobar distribution of emphysema (U/L ratio).
Airway disease was assessed using VIDA software (VIDA Diagnostics, Inc.; www.vidadiagnostics.com) as gas trapping (percentage of low attenuation units < -856 Hounsfield units [HU] at end-expiration), airway wall thickness (obtained along the center line of the lumen, in the middle third of the airway segment, for one segmental airway of each lung lobe; the mean value across all lobes was used for analysis), and Pi10 (the square root of the wall area of a hypothetical airway of 10-mm internal perimeter).
Although small airway disease can be assessed by gas trapping, a significant limitation of this approach is that many lung regions that trapped gas on exhalation will also show emphysematous destruction when fully inflated to total lung capacity. 12 We therefore also analyzed data from a recently developed CT analytic method, Parametric Response Mapping (PRM) by Imbio LLC, using Lung Density Analysis software (Imbio LLC). 13 By coregistering inspiratory and expiratory CT images, the PRM method discriminates emphysema (PRM-emphysema) from nonemphysematous air trapping, termed functional small airways disease (PRM-fSAD).
14 These PRM measurements were available for 3,073 subjects at visit 1 and 2.
Clustering and Statistical Analyses
Emphysema variables from visit 1 were log(xþ1) transformed to reduce the impact of deviations from normality. To account for emphysema severity and generate lobe-specific measures, each lobar emphysema variable was regressed on total emphysema. Unsupervised random forest clustering was then performed on the residuals, using the approach described by Shi and Horvath. 15 The identified clusters were tested for associations with visit 1 and visit 2 characteristics. The definitions of the various COPD characteristics and comorbidities are shown in e- Table 1 . The longitudinal outcomes were calculated by subtracting the visit 1 value from the visit 2 value. Negative values represent a lower value of the outcome at visit 2.
Using PLINK, version 1.9, a GWAS was conducted comparing upper-lobe vs lower-lobe clusters adjusting for pack-years of smoking, current smoking, sex, and principal components of genetic ancestry. 16 Separate results in non-Hispanic white and African American subjects were combined using fixed-effects meta-analysis implemented in METAL software (August 8, 2010) . 17 We also evaluated associations with 25 genetic variants previously associated with COPD susceptibility, emphysema, or emphysema distribution ("candidate single nucleotide polymorphism [SNP] analysis"). 7, 8, [18] [19] [20] [21] [22] [23] [24] Additional methods are available in e-Appendix.
Results
Characteristics of Study Participants Included in the Analyses
We included in the analysis 9,210 smokers (6, 195 nonHispanic whites and 3,015 African Americans) with complete lobar imaging and phenotypic data from visit 1. The characteristics of these subjects are shown in e- Table 2 . Compared with non-Hispanic whites, African American subjects were slightly younger and had a lower median exposure to smoking, a higher FEV 1 % predicted, less severe total emphysema, and less advanced COPD.
Cluster Analysis
When the clustering variables were visualized using principal components analysis (PCA), it was apparent that subjects are spread along a continuum of emphysema distribution, and standard approaches that classify all subjects would not be guaranteed to identify a core of tightly clustered subjects (Fig 1) . Based on this observation, we applied an unsupervised random forest clustering method designed to identify tightly clustered subjects and remove poorly clustered observations. This algorithm identified three clusters consisting of 3,013 subjects. Clustering criteria were not met in 6,197 subjects. The characteristics of these subjects, shown in e-Table 3, demonstrate that this "poorly clustered" group encompasses subjects across the range of COPD severity (GOLD 0-GOLD 4) with less total emphysema than either the upper lobe-predominant or lower lobepredominant groups. Most importantly, the members of this group have neither marked upper-lobe or lowerlobe emphysema predominance (U/L ratio, Fig 1) . No difference in airway wall thickening or Pi10 was noted among the three clusters, but both upper lobe-predominant and lower lobe-predominant subjects had more gas trapping compared with subjects with minimal emphysema. e- Table 4 includes detailed characteristics of these subgroups.
Visit 1 Demographic, Physiological, and Clinical Characteristics
Relative to subjects with upper-lobe predominance, those in the lower-lobe cluster were slightly older, more likely to be non-Hispanic white, had more severe airway obstruction, and had a higher prevalence of metabolic syndrome. There was no significant difference between the upper-lobe and lower-lobe clusters regarding smoking exposure and exacerbation frequency ( Table 1) . The "minimal emphysema" cluster contained predominantly female subjects with fewer pack-years of chestjournal.org smoking, minimal airway obstruction, more obesity, low comorbidity burden, and mildly impaired health-related quality of life.
Five-Year Prospective Change in Imaging
The 5-year changes in imaging measures are shown in Table 2 . Over the 5-year follow-up, a more rapid progression of % LAA-950 was observed in subjects with upper-lobe predominance compared with those with lower-lobe predominance (absolute increase of 1.05% vs -0.01%; P < .001). The changes in emphysema as a percentage of emphysema at baseline are shown in e- Table 5 . Although the absolute increase in emphysema in the group with upper-lobe predominance was modest, the percentage increase in emphysema was notable (emphysema change relative to visit 1, 23% vs -0.1%; P < .001), reflecting the fact that roughly half of the group with upper-lobe predominance had < 5% emphysema at baseline. These differences in radiological changes remain significant with a consistent direction of effect after accounting for age, sex, race, BMI, pack-years of smoking, change in smoking status between the two visits, and the baseline level of each respective outcome (Table 3 ). The emphysema distribution pattern remained similar between visit 1 and visit 2 with minimal change noted in the U/L ratio between the two visits for the upper lobe-predominant and lower lobe-predominant clusters (Table 2 ). Since CT emphysema measures were calculated with implementation of different software at visit 1 and visit 2, Thirona and SLICER % LAA-950 values were compared in 5,000 visit-1 scans processed by both methods, and the correlation was 0.99. A more rapid progression of PRM-emphysema and PRM-fSAD was observed in subjects with upper lobe predominance compared with those with lower lobe predominance (absolute change, 0.92% vs 0.04%; P < .001 for PRMemphysema and 1.56% vs 0.11%, P ¼ .01 for PRM-fSAD) (e- Table 6 ).
Using stratified analyses, we explored how the relationship between emphysema distribution and emphysema progression is modified by GOLD grade, overall severity of emphysema, BMI, and current smoking. Interestingly, in the lower-lobe cluster, radiological decline was inversely associated with BMI, although the differential associations of upper-lobe clusters vs lower-lobe clusters with total emphysema and emphysema distribution were consistent across BMI strata (e- Table 7 ). Although more severe in the subjects with total emphysema > 5% (e-Table 8), radiological progression was similar at all GOLD grades (e- Table 9 ). As noted in Table 2 , the differences in the % change of gas trapping between visit 1 and visit 2 in the upper-lobe vs lower-lobe clusters had a P value of .17 in current smokers and .08 in former smokers. The differences in the % change of CT-total lung capacity had a P value of .16 in current smokers and .02 in former smokers. Conversely, the differences in the % change of total A B Figure 1 -Principal components analysis (PCA) plot of the residualized lobar emphysema variables. A, The three identified clusters: the minimal emphysema cluster is in red, the upper lobe-predominant emphysema cluster is in gray, and the lower lobe-predominant emphysema cluster is in blue. B, The unassigned group is in orange. To summarize the relationships between the five residualized lobar emphysema variables, we performed PCA on these data. The top two principal components (PC) explained almost 80% of the variance in these data (50.7% for PC1 and 26.2% for PC2). PC1 represents an "upper lobe emphysema axis," and PC2 is a "lower-lobe emphysema" axis, based on their positive loadings for each kind of emphysema, respectively. Table 3 ). The statistically significant difference seen in the univariate analysis of FEV 1 (mL/y) was attenuated after adjustment for potential confounders. Stratified analyses suggest that the difference in FEV 1 decline between the group with upper-lobe predominance and the group with lower-lobe predominance is greatest in early GOLD grades (e- Table 8 ).
Genome-Wide Association Studies
The quantile-quantile plot of the P value distributions and genomic control values demonstrated absence of a systematic inflation (e -Fig 2) . No SNPs reached genomewide significance. However, regions of interest were identified near genome-wide significance, with SNPs at meta-analysis P values < 5 Â 10 -6 (e- Table 10 ).
Nominally significant associations were observed near the HHIP, AGPHD1, PPT2/AGER, TRAPPC9, MYO1D, KIAA1462, and IREB2/CHRNA3/5 genes (Table 4) . Interestingly, for four of the five loci with nominally significant associations with both emphysema distribution subtypes and COPD, the COPD risk allele is associated with upper-lobe predominance.
Discussion
In this large cohort of smokers without alpha-1-antitrypsin deficiency, random forest clustering identified tightly clustered groups of subjects with distinct craniocaudal emphysema distribution patterns but similar degrees of total emphysema, measurable airway disease, and cigarette smoking. Compared with lower lobe-predominant emphysema, subjects with mostly upper-lobe emphysema had less severe lung function impairment and lower rates of obesity and metabolic syndrome at baseline but greater progression of radiological emphysema, gas trapping, and dyspnea after 5 years of follow-up. These two clusters also demonstrated different patterns of association with established COPD genetic risk variants.
Data mining methods such as cluster analysis enable the identification of discrete groups of patients with similar disease characteristics. These techniques have been previously used in COPD, but no investigation to date has focused on emphysema distribution. [25] [26] [27] In a recent study, Castaldi et al 28 directly assessed the reproducibility of different clustering methods applied commonly to COPD clinical variables in 10 independent cohorts of patients with COPD. This analysis revealed that there was higher reproducibility for clustering methods that excluded individuals who did not clearly belong to any cluster. Based on these novel findings, we selected the random forests clustering approach used for this study precisely because of its ability to discriminate well-clustered from poorly clustered subjects. Thus, our primary goal for this project was not to cluster all subjects with COPD but rather to identify relatively pure subgroups of subjects characterized by upper or lower emphysema predominance. The clustering approach used here was able to identify clearly differentiated upper lobe-predominant and lower lobe-predominant emphysema subgroups that had a similar extent of total emphysema, airway disease, and cigarette smoking, enabling the further characterization of these specific subgroups. These subgroups would not have been identified with the more traditional approach of thresholding based on differences or ratios in the percentages of emphysema in upper vs lower lobes.
Our findings are consistent with prior reports of more severe airway obstruction in lower zone-predominant emphysema and are reflective of the dominant contribution of the lower lobes to the forced expired maneuver. [29] [30] [31] [32] Since most of these studies included more advanced stages of COPD, our observations extend those findings to subjects with mild to moderate COPD. Investigating 115 smokers with mild to moderate COPD (58 of whom had emphysema), de Torres et al 33 did not demonstrate any significant association between craniocaudal emphysema distribution and lung function parameters, likely because of the smaller sample size and the differences in the methods of assessing emphysema distribution compared with our study.
To our knowledge, this is the first report of an association between an upper-lobe emphysema subtype and faster rates of overall emphysema progression. In a cohort of 587 male smokers followed for 3 years, a faster spirometric decline was observed in upper-lobe emphysema compared with lower-lobe emphysema, but emphysema progression was not assessed. 34 Our study also demonstrated an association between upper-lobe emphysema and more rapid disease progression, but our significant findings were primarily limited to emphysema progression. Although we did observe a significant univariate association demonstrating more rapid decline in FEV 1 (mL/y) in the group with upperlobe predominance, this association was no longer significant after adjustment for baseline FEV 1 . Bhatt et al 14 showed that decline in FEV 1 in mild to moderate disease is associated with airway disease and emphysema, and in our study, the upper-lobe and lower-lobe clusters had similar degrees of measurable airway disease and overall emphysema, potentially explaining the lack of significant difference in FEV 1 decline between the two clusters.
Diabetes and the metabolic syndrome are frequent comorbidities in patients with COPD. These comorbidities have been shown to be more frequent in airway-predominant COPD, 35, 36 and this study extends those results to subjects with lower lobe-predominant Model 2 includes the following covariates: visit 1 value of the outcome of interest, change in smoking status between visit 1 and visit 2, age, sex, race, BMI, and pack-years of smoking. Change in smoking status between visit 1 and visit 2 was defined as: "Current to former smoker", "former to current smoker", "current; unchanged", or "former, unchanged". A total of 25 SNPs were considered in this analysis. They were selected on the basis of previously published genome-wide significant associations with COPD case-control status, qualitative or quantitative CT measurements of emphysema, and emphysema distribution. The analyses were adjusted for pack-years of smoking, current smoking, genetic ancestry, and sex. OR was calculated with the upper-lobe predominant cluster as the reference group in the upper-lobe vs lower-lobe GWAS, and COPD cases were the reference group in the case-control GWAS. P values < .05 are bold. GWAS ¼ genome-side association study; NA ¼ not available; SNP ¼ single nucleotide polymorphism.
a The present study.
b
The published GWAS of COPD case-control status.
emphysema. These comorbidities are all related to systemic inflammation, which may explain the co-occurrence. It is also possible that this is a reflection of worse lower-lobe mechanics leading to more immobility, obesity, and associated cardiovascular disease.
In our prior GWAS of emphysema distribution, 8 we identified five loci associated with continuous emphysema distribution measures at genome-wide significance. In this current study, we sought to supplement these findings by determining the genetic associations in distinct groups of subjects with upper lobe-predominant vs lower lobe-predominant emphysema, but we did not identify any novel genomewide significant associations, likely because this analysis was limited to a subset of subjects from the overall cohort and therefore had less power to detect genetic associations. In addition to the top GWAS signals, we chose to also report the associations with SNPs already known to be associated with COPD or emphysema, since these SNPs are already of interest to the study of COPD and its related phenotypes. Although the number of nominally significant associations in this set of known COPD/emphysema variants suggests that genome-wide significant associations may be identified with a larger sample size, these non-genome-wide significant associations should be interpreted cautiously.
One of the interesting findings from this analysis is the observed higher prevalence of the COPD risk allele in subjects with upper-lobe predominance that suggests a potential link between upper-lobe predominance and common risk variants for COPD. As suggested by the pathway analyses that we reported in our previous publication, 8 emphysema distribution shares some of the processes that occur in general COPD pathogenesis and progression, but other pathways may be specific to the pathogenesis of emphysema distribution. The precise reasons for the upper lobe predominance in smokers without alpha-1-antitrypsin deficiency and emphysema are unclear, but it has been attributed to regional differences in perfusion, transit time of leukocytes, clearance of deposited dust, mechanical stress, and pleural pressure. 20, 24, 37, 38 It is also noteworthy that in this current manuscript, we analyzed common genetic variants only (ie, variants with major allele frequency > 1%) and had limited power to detect small effect sizes. We therefore cannot exclude the possibility that rare genetic variants or common variants with smaller effect sizes, or both, are involved and have differential associations with COPD susceptibility and emphysema distribution.
Our study has a number of strengths. It is the first study designed to identify emphysema distribution subtypes using data-driven methods, and it is the largest analysis to date of emphysema distribution in well-characterized smokers with a wide range of COPD disease severity and longitudinal follow-up data. In addition, the lobar segmentation approach used to generate our emphysema measures was shown to provide improved characterization of emphysema distribution compared with nonanatomic approaches. 39 This study has several limitations. First, we focused exclusively on craniocaudal emphysema distribution variables. However, other measures of emphysema distribution have been described in the literature, such as core-rind and centrilobular/panlobular/paraseptal distributions 40 and warrant future explorations. Second, unsupervised clustering is an exploratory analysis method, and the generalizability of these results to other cohorts cannot be assumed. Third, BMI has a strong inverse association with total emphysema 14, 30, 40 and may also confound emphysema measures due to technical artifact induced by scatter effects. 41, 42 However, apicobasal emphysema is effectively standardized within the same subject, making this measure more likely to be robust to technical artifacts than is total emphysema. 41 In addition, most of our observed associations remained significant after adjusting for BMI.
In conclusion, this cluster analysis using lobar emphysema identifies subgroups of smokers that differ by craniocaudal emphysema distribution patterns, disease progression, and genetic associations. These findings may be of importance in optimizing participant selection in future clinical trials to ultimately improve and personalize therapy.
